



Adjuvant systemic therapy

P001 Neratinib as extended adjuvant therapy in patients with HER2-positive/HR-positive early breast cancer: German HTA-driven analyses from the ExteNET study	Diana Lüftner
P002 Evaluation of the efficacy of Trastuzumab in patients with HER2 positive small (pT1mi/a) breast cancers. A multicenter retrospective study on 100 patients	Andrea Villasco
P003 Extended adjuvant treatment of patients with HER2+ early breast cancer with neratinib: a multi-centric, prospective, non-interventional study (NIS) in Germany and Austria (ELEANOR)	Rupert Bartsch
P004 Bringing diarrhea under CONTROL: dose escalation reduces neratinib-associated diarrhea and improves tolerability in HER2-positive early-stage breast cancer	Manuel Ruiz-Borrego
P005 Continued efficacy of neratinib in patients with HER2-positive (HER2+) early-stage breast cancer: final overall survival (OS) analysis from the randomized phase 3 ExteNET trial	Miguel Martin
P006 Prescribing practices of endocrine therapy for premenopausal breast cancer patients in Mexico	Cynthia Villarreal-Garza
P007 (Trial in progress) A real-life prospective, observational, post-authorisation safety study in adult breast cancer patients treated with neratinib in extended adjuvant in Europe: the NERLYFE study	Roberta Valenti
P008 Patients' quality of life and side effect perceptions in monarchE, a study of abemaciclib plus endocrine therapy in adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer	Sara Tolaney
P009 5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial	Joseph Gligorov
P010 The role of genomic studies in breast cancer: the reality of a Portuguese hospital	Aurea Lima
P011 Post neoadjuvant HER2 treatment: real world data from a multicentric cohort	Paulo Luz
P012 Tolerance and outcome of hypofractionated whole breast irradiation in young women: from controversies to evidence	Dorra Aissaoui
P013 Safety outcomes from monarchE: Phase 3 study of abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high risk, early breast cancer	Hope S. Rugo

Biology/Pathology/Basic Research

P014 Biology of breast cancer after in vitro fertilization (IVF)	Maxim Izquierdo
P015 Exploring the effects of mastectomy on the sexual health and marital relationship of adult married women at a tertiary care hospital in Karachi, Pakistan	Kausar Karim
P016 Ipsilateral breast cancer recurrence: characteristics, treatment, and long-term oncological results at a high volume center	Damiano Gentile
P017 Early Breast Cancer Recurrence Score: comparison between Endopredict and Magee Equations in a real-world general hospital	Isabel Betancor-Fernandez
P018 Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via AKT/mTOR signaling pathway	Joseph Lin
P019 Single nucleotide polymorphisms rs17335780 and rs11979255 of the epidermal growth factor receptor (EGFR) correlate with tumor size in breast cancer	Monika Sobočan
P020 Upregulation of SLC26A9 resulted in the development and progression of HER2-positive breast cancer via activating PI3K/AKT signaling pathway	Zhiyuan Ma
P021 Single-cell transcriptome sequencing analysis reveals gynaecomastia to breast cancer transition	Handong Sun



P022 RANK-c expression in ER-negative breast cancer cells alters sensitivity to tyrosine kinase inhibitors	Chaido Sirinian
P023 Expression of RANK-c in ER-/HER2+ breast cancer cells affect aggressiveness through altering the NF-κB equilibrium	Chaido Sirinian
P024 Lymphoid environment in Luminal A subtype invasive ductal breast carcinoma	Liliya Volos
P025 E-cadherin expression in triple-negative invasive ductal breast carcinoma	Liliya Volos
P026 Immunohistochemistry pattern for suppressor tumor and DNA repair genes as screening tool for hereditary breast cancer tracking	Paulo Goberlânio de Barros Silva
P027 TIL's in triple-positive breast cancer	Maria Urezkova
P028 Analysis of normal tissue complication probability-based radiobiological models: a systematic review of literatures	Mahfuzur Rahman
P029 Omission of radiation therapy after breast conserving surgery in older early breast cancer among Sudanese patients	Shaimaa Siddig
P030 Tumor angiogenesis: miRNAome abnormalities deregulate expression of angiogenic genes in breast cancer cells and contribute to increased formation of new but imperfect blood vessels	Volodymyr Halytskyi
P031 Physician survey in the treatment of HR+/HER2- metastatic breast cancer in Egypt	Eman Aboelkheir
P032 MammaPrint risk score distribution in South African breast cancer patients with the pathogenic BRCA2 c.7934delG founder variant: towards application of genomic medicine at the point-of-care	Iwando Mampunye
P033 Clinicopathological and molecular subtypes of early breast cancer in young women in Sudan	Shaimaa Siddig

Epidemiology/Prevention/Diagnosis

P034 Analysis of exhaled volatile organic compounds: a new frontier in breast cancer screening and surveillance	Alexandra Allard-Coutu
P035 Breast cancer recurrence and survival: what, when and where, a 17-years retrospective cohort	Amirreza Ehsani
P036 An ultra low cost vacuum assisted core needle biopsy technique for breast lumps: a pilot study in a resource limited setting	Sanjay Kumar Yadav
P037 Assessment and reimbursement of gene expression tests in breast cancer in Europe – a comparative policy analysis	Kirsten Herrmann
P038 Scenarios of cost-savings associated with Oncotype DX® test-guided decisions for adjuvant chemotherapy in early breast cancer in Germany	Kirsten Herrmann
P039 Factors associated with breast cancer screening awareness and participation among West Java Indonesian	Yohana Azhar
P040 Relationship between altered myoepithelial phenotype and the inflammatory cell infiltrate in progression of DCIS	Khairiya Ohaida
P041 Evaluation of sentinel lymph node by sonography	Toshio Hashimoto
P042 Breast screening in BRCA1/2 carriers leads to earlier detection and superior therapy of breast cancers	Shay Shraga
P043 Validation of liquid biopsy for ESR1-mutation analysis in hormone-sensitive breast cancer: a pooled meta-analysis	Omar Najim
P044 Monoallelic MUTYH mutations and hereditary breast cancer - results of an epidemiologic study in Brazil	Rosane de Sant'Ana
P045 Emotional implications of women in the gene panel for hereditary cancer	Paulo Goberlânio de Barros Silva
P046 Marked reduction in the risk of dementia in patients with breast cancer: a nationwide population-based cohort study	Chang Ik Yoon
P047 Real-word study on HR+, HER2-, node-positive, high-risk early breast cancer (EBC) in France: patient profiles, management and treatment patterns	Xavier Pivot
P048 Breast cancer surveillance in women with PTEN Hamartoma Tumour Syndrome (PHTS)	Alma Hoxhaj
P049 Methylation signatures with diagnostic value in breast cancer via automated machine learning	Maria Panagopoulou
P050 Adiposity and risk of breast cancer in Chinese women	Christiana Kartsonaki
P051 Intrinsic tumor subtype and diagnostic performance of conventional breast imaging technique for the detection of unifocal breast cancer	Claudia Stanciu Pop
P052 Quality of life in breast cancer patients – evidence from South India	Sabin Katpattil
P053 Quality of life among young breast cancer patients	Asmin Sha
P054 Epidemiological and clinical characteristics of breast cancer in the southern of Tunisia: about 1067 cases	Wala Ben Kridis
P055 Differences of breast tumour localization and size between supine and prone breast MRI for a surgery perspective	Ceyda Civan Kus



Locally advanced disease

P056 Efficacy of fulvestrant in hormone refractory metastatic breast cancer (mBC): a Canadian province experience	Samitha Andrahennadi
P057 The efficacy and safety of Tyrosine kinase inhibitors in HER-2 positive breast cancer with brain metastases: a systematic review and meta analysis	Jie Zhang
P058 The significance of skin edema in advanced breast cancer and its response to neoadjuvant chemotherapy	ISHITA LAROIYA
P059 The efficacy and safety of dual HER2 blockade with a pertuzumab-based regimen for metastatic breast cancer patients previously exposed to an anti-HER2 agent: a systematic review and meta-analysis	Shanshan Chen
P060 Are clinical and molecular features similar in inflammatory breast cancer and non-inflammatory breast cancer?	Dorra Aissaoui
P061 Metaplastic breast cancer, an urgent need for novel therapies	Arwa Ashoor
P062 Clinical response and pathological evidence of treating metastatic breast cancer with immunotherapy using stimulated natural dendritic cell pulsed with neoantigen peptides	Kris Chatamra
P063 Treatment strategy for locally advanced breast cancer in our department	Hideaki Komatsu

Radiotherapy/IORT

P064 Effects of IORT and EBRT methods on local recurrence control in breast cancer patients using Weibull regression model	Nahid Nafissi
P065 Hypofractionated radiation therapy after radical mastectomy: predictive factors of acute skin toxicity	Raouia Ben Amor
P066 The difference between patient's and population's preferences for early staged breast cancer radiation therapy, focus on EBRT vs. IORT treatment options - qualitative research method	Velko Stoimenov
P067 Radiotherapy of ductal carcinoma in situ after conservative surgery: what is the role of the boost?	Raouia Ben Amor
P068 Role of hypofractionated tumor bed boost in the era of short course radiotherapy in early stage breast cancer	Ankita Pandey
P069 Role of time factor between External Beam Radiotherapy alone versus External Beam in combination with brachytherapy boost in breast cancer patients after breast conserving surgery	Ankita Pandey
P070 Dosimetric impact due to volumetric changes of the breast during whole breast irradiation	Kyung Ran Park
P071 Impact of irradiation of the internal mammary lymph nodes on heart and lung doses	Dorra Aissaoui
P072 Breast reconstruction and radiation therapy: consensus statements of the Italian association of radiotherapy and clinical oncology (AIRO) breast cancer group	Icro Meattini
P073 Should we delineate coronary arteries in right-sided breast cancer radiotherapy?	Zeineb Naimi
P074 Radiation dose distribution in cardiac valves in left-sided breast cancer radiotherapy	Zeineb Naimi
P075 Evaluation of the effect of axillary radiotherapy dose and the development of lymphodema in breast cancer patients	Omnia Ali Elemary
P076 Dynamics of circulating tumor DNA during postoperative radiotherapy for triple-negative breast cancer in patients undergoing neoadjuvant chemotherapy and breast surgery	Haeyoung Kim



Neoadjuvant (pre-operative) therapy

P077 Comparisons of efficacy and safety of nanoparticle albumin-bound paclitaxel and docetaxel neoadjuvant regimens for treating breast cancer: a retrospective real-world study conducted in China	Xiaoming Zha
P078 Application of conventional ultrasonography combined with contrast-enhanced ultrasonography in the lymph nodes and evaluation of the efficacy of neoadjuvant chemotherapy in breast cancer patients	Guoqiang Zhang
P079 Efficacy and safety of neoadjuvant therapy for HER2-positive early breast cancer: a network meta-analysis	Jie Zhang
P080 Efficacy and safety of neoadjuvant therapy for Triple-Negative Breast Cancer (TNBC): a Bayesian network meta-analysis	Jie Zhang
P081 A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, and immunogenicity of ABP 980 and pertuzumab combined in a single infusion in healthy subjects	Vladimir Hanes
P082 Her-2 positive and TNBC patients receiving neoadjuvant chemotherapy are associated with a high pathological complete response rate - results from real-world outcomes in a multidisciplinary setting	Bernardo Leon Rapoport
P083 Breast and axillary downstaging after neoadjuvant chemotherapy in breast cancer: surgical technique	Andrea Villasco
P084 One size fits all? Novel pulse biopsy platform offers improved needle control, high tissue yield and multiple needle options – pre-clinical results	Stefan Paepke
P085 Clinical and pathological response to neoadjuvant chemotherapy (NCT) in patients with triple negative breast cancer (TNBC)	Petr Krivorotko
P086 Phase II neoadjuvant trial of Albumin-Bound Paclitaxel, Trastuzumab and Pertuzumab followed by anthracycline based regimens in patients with operable Her2 positive breast cancer (OMC-BC05)	Mitsuhiko Iwamoto
P087 Assessment of endocrine sensitivity in primary breast cancer through RS Score and changes in the proliferation index KI67	Ariadna Gasol Cudos
P088 5-yr DMFS outcomes on the pre-operative use of MammaPrint and Blueprint for neoadjuvant decisions in the NBREaST II trial	Emine Göker
P089 Margins and outcomes in breast conserving surgery after neoadjuvant chemotherapy treated with whole breast radiation	Jun-Hee Lee
P090 Pathological complete response in early stage HER-2 positive breast cancer patients, receiving neoadjuvant chemotherapy/Trastuzumab, in a single breast unit in Johannesburg	Alessandro Bellomo
P091 Assessment of pathological complete response using vacuum assisted biopsy in breast cancer patients who have clinical and radiological complete response after neoadjuvant chemotherapy	Siddhant Khare
P092 Analysis of primary endocrine therapy in breast cancer patients over 70 years from a single unit in South Africa: analysis of those that choose no surgery first. Highlighting COVID-19 sensitive issues	Carol Benn
P093 Neo-adjuvant chemotherapy in luminal, node positive breast cancer: characteristics, treatment, and oncological outcomes. A single center's experience	Erika Barbieri
P094 Predicting pathological complete response in the axilla post neoadjuvant chemotherapy in carcinoma breast	AfrAh AbduRahman
P095 Neoadjuvant niraparib in patients with HER2-negative, BRCA-mutated resectable breast cancer	Hyo Han
P096 Microcalcifications after neoadjuvant chemotherapy for breast cancer in women achieving pathologic complete response of the invasive disease: do they matter?	Tanja Johanna Gagliardi
P097 Limited indication for neoadjuvant chemotherapy for patients with specific morphological and clinical factors on the basis of individualized exclusion criteria	Marcin Śniadecki
P098 Tumor biology not stage dictates treatment choice: an analysis of NAPBC accreditation data from South Africa	Carol Benn
P099 Impact of treatment choices based on cancer biology for neoadjuvant breast cancer patients at a multidisciplinary unit in Johannesburg, South Africa	Carol Benn
P100 Results of darbepoetin alfa treatment of anaemia in chemotherapy-receiving early breast cancer patients - one-centre retrospective observational study	Agnieszka Gruszfeld



Health politics/Guidelines

P101 Two-phased strategy for improvement of breast cancer care in Bangladesh	Masuma Sarker
P102 Effect of accreditation best practice systems on time to treatment delays: three-year review of a South African internationally accredited site	Carol Benn
P103 Hospital vs community screening for breast cancer	Gaurav Pydisetty
P104 Strategies for breast cancer surgery during & after COVID-19 pandemic	Arwa Ashoor
P105 A cost-effectiveness analysis of trastuzumab in Taiwanese patients with stage II-III HER2-positive breast cancer and axillary node metastasis	Wesley Chou

Predictive and prognostic factors

P106 The effects of prognostic factors on metastasis and survival of patients with breast cancer using a multi-state model	Ebrahim Babaee
P107 Breast cancer after in vitro fecundation (IVF): can ovary stimulation and follicular response affect prognostic factors?	Maxim Izquierdo
P108 Predictive mathematical modelling of recurrence periods for the secondary distant metastases in patients with ER/PR/HER2/Ki-67 subtypes of breast cancer	Ella Tyuryumina
P109 Effectiveness of breast-conserving treatment for minimal residual tumors after neoadjuvant breast cancer therapy	Roman Pesotsky
P110 Evaluation of incidental implantation of tumor cells after diagnostic needle biopsy in breast cancer patients	Haruhi Maseki
P111 Comparing MammaPrint and Blueprint results between core needle biopsy and surgical resection breast cancer specimens	Miranda Kleijn
P112 MammaPrint, Blueprint, and full-genome data linked with clinical data to evaluate new gene EXpression profiles (FLEX): a real-world dataset and investigator-initiated protocols in ESBC	Jennifer A Crozier
P113 Survival comparison of HER2 breast cancer patients according to HR status: analysis of a single Portuguese centre	Gonçalo Nogueira-Costa
P114 The evaluation of tumor-infiltrating lymphocytes (TILs) in early breast cancer: differences between histologic subtypes in a Portuguese cohort	Paulo Luz
P115 Polymorphisms in antioxidant genes as predictive factors of radiotherapy late skin adverse events in breast cancer patients	Tanja Marinko
P116 Predicting clinical behaviour of breast phyllodes tumors: utility of Singapore nomogram	Jaiprakash Gurawalia
P117 Implementation of a pathology-supported genetic testing framework for return of research results to family members of deceased breast cancer patients with somatic TP53 variants	Kelebogile, E Moremi
P118 The role of tumor-infiltrating lymphocytes, prognostic and predictive signification in breast cancer	Andrey Tseluiko
P119 The level of adherence to medical standarts as a prognostic factor for breast cancer recurrence	Vanya Mitova
P120 Neutrophil-lymphocyte ratio and nodal pathologic complete response in node positive breast cancer patients undergoing neoadjuvant chemotherapy	Maria Luisa Gasparri
P121 Clinicopathological characteristics and recurrence patterns among young and very young breast cancer patients in Middle East	Abeid M. Athman Omar
P122 The Oncotype DX® assay use in breast cancer in an Australian institutional setting	Joseph Do Woong Choi



Surgery/Sentinels/DCIS

P123 Factors affecting sentinel lymph node metastasis in patients with breast cancer undergoing sentinel lymph node biopsy before or after systemic therapy	Lutfi Dogan
P124 Axillary reverse mapping in the prevention of lymphoedema: a systematic review of randomized trials	Michael Co
P125 Clinical significance of discordances in sentinel lymph node reactivity between radioisotope and indocyanine green fluorescence in cNO breast cancer patients	Kenjiro Jimbo
P126 The effect of primary surgery in patients with stage IV breastcancer with bone metastasis only (protocol bomet MF14-01); a multi-center, registry study	Lutfi Dogan
P127 Survival after breast conservation versus mastectomy adjusted for comorbidity and socioeconomic status: national 6-year follow-up on 48986 women	Jana de Boniface
P128 Angiosome theory findings using new protocol of CT-angiography improves outcomes in DIEP-flap reconstruction surgery in breast cancer patients	Roman Pesotsky
P129 Retrospective evaluation of immediate postmastectomy breast reconstruction with Tiloop BRA. Our experience with 103 patients	Roman Pesotsky
P130 Appropriateness of handheld Doppler in identification of chest wall perforator for partial breast reconstruction	Neerja Gupta
P131 Comparing the temporal changes of cosmetic, QoL and patient satisfaction achieved with breast reconstruction and contralateral symmetrisation techniques. (ClinicalTrials.gov: NCT04356235)	Mihály Újhelyi
P132 The long term outcome of patients on primary endocrine therapy	Lynsey Williams
P133 The assessment of primary breast cancer tumor size by magnetic resonance imaging, breast ultrasonography and mammography: a comparative study across intrinsic tumor subtype	Catalin Florin Pop
P134 Retrospective multicenter analysis comparing conventional with oncoplastic breast conservation: oncologic and surgical outcome in women with high risk breast cancer from the OPBC-01/iTOP2 study	Florian Fitzal
P135 Management of patients with residual microcalcifications and false-negative results after stereotactic vacuum – assisted biopsy of mammographic suspicious microcalcifications	Georgios Kinoglou
P136 Ductal carcinoma in situ (DCIS) and breast cancer-specific and all-cause mortality among postmenopausal women in the Women’s Health Initiative	Rowan Chlebowski
P137 Autologous breast reconstruction with free flaps in patients with oligometastatic breast cancer: when to proceed and when not?	Olivia Sjkovist
P138 Evaluation of the impact of the COVID-19 pandemic on the practice of axillary node dissection	Grant Harris
P139 Surgical and oncologic outcomes of robotic and conventional nipple-sparing mastectomy with immediate reconstruction: pooled analysis of individual patient-level data from international multi-centers	Jeea Lee
P140 Savi scout radar versus wire-guided localisation in breast cancer surgery: a systematic review and meta-anaylsis of surgical outcomes	Ahmed Latif
P141 Reverse abdominoplasty flap in reconstruction of anterior chest wall defects post extensive mastectomies	Ibrahim Sallam
P142 Is number of sentinel nodes enough after neoadjuvant chemotherapy?	Sofía Aragón
P143 Would clipping and removal of all ultrasound abnormal metastatic lymph nodes predict nodal response in breast cancer patients with neoadjuvant chemotherapy?	Geok hoon Lim
P144 Radiological evaluation of surgical margins after lumpectomy: comparison between mammography and ultrasound	Stephanie Gentile
P145 Video-endoscopic single-port breast surgery: personal experience	Laura Roveda
P146 Omitting axillary lymph node dissection in breast cancer patients with metastatic sentinel node after neoadjuvant chemotherapy	Bekir Kuru
P147 Use of indocyanine green (ICG) in detection of axillary sentinel lymph nodes for breast cancer	Christina Nikolauou
P148 Conservatives mastectomies and immediate direct to implant breast reconstruction during COVID-19 pandemic: the strategy of the Breast Center Villa Tiberia Hospital	Dimitrios Varvaras
P149 Pre-pectoral breast reconstruction and complete implant coverage with a new bovine acellular pericardium matrix: Breast Center Villa Tiberia Hospital experience	Dimitrios Varvaras
P150 Role of SPECT/CT in detection of the marked metastatic lymph node and the sentinel node, after neoadjuvant chemotherapy in patients with breast cancer	Ece Dilege



Survivorship issues

P151 Evaluation of an end of treatment summary in patients with early breast cancer: quality improvement project	Katharine Nsiah
P152 Reproductive outcomes in young breast cancer survivors treated (15-39) in Ontario, Canada: a population-based study	Moirá Rushton-Marovac
P153 Multimorbidity patterns among long-term breast cancer survivors: a Spanish population-based study	Anna Jansana
P154 Oncophone20 study: patients perception of telemedicine during follow up visits	Alessandra Surace
P155 Adherence to follow-up recommendation guidelines in long term breast cancer survivors, a SURBCAN cohort analysis using administrative databases	Paula Santiá
P156 Impact of endocrine therapy on quality of life in early stage breast cancer patients: prospective patient reported outcomes from the international registry INSPIRE	Isabel Rubio
P157 Long-term trastuzumab treatment in HER2 positive metastatic breast cancer	Marina Calamac

Other

P158 Metabolic activity of breast cancer cells in primary tumor models in vitro	Tetiana Herheliuk
P159 Totality of evidence for ABP 980, a trastuzumab biosimilar: results of chemo-synergy studies in combination with pertuzumab	Hans-Christian Kolberg
P160 Correlation of breast imaging and pathological subtype of young breast cancer under 35 years old	Teerawut Rakchob
P161 The secondary use and linking of health administrative and clinical trial data in cancer: attitudes towards data reuse in Australia	Elizabeth Hutchings
P162 Caloric restriction, physical and creative activities against breast cancer: our pilot study	Aurelia Mondino
P163 Impact of the COVID-19 outbreak on the level of distress in patients with breast cancer	Anuska Budisavljevic
P164 Line of therapy adjustment in a patient with advanced triple-negative breast cancer (TNBC) by using personalized ctDNA test for treatment response monitoring	Georges Azzi
P165 Is metaplastic breast cancer more aggressive than “classic” triple-negative ductal carcinoma? Recent prognostic and therapeutic consideration	Antonia Girardi
P166 Do residual radionuclides following the Chernobyl accident lead to a distinct subtype of breast cancer?	Sunreet Randhawa
P167 A multi-functional portable system for diagnosing breast cancer from ex-vivo biopsy tissues	Vishnu Kurpad
P168 Assessing the Impact of the COVID-19 outbreak on the oncological practice regarding metastatic breast cancer patients treated with CDK4/6 inhibitors	Menna Fouda
P169 Breast cancer surgery in COVID19 outbreak: the role of therapeutic mastoplasty	Eleftherios Sfakianakis
P170 Ultrasound-guided cryoablation as substitute for surgery in elderly patients with non resected breast cancer: pilot study with medium-term outcomes	José María Oliver-Goldaracena
P171 Frequency and spectrum of mutations in the BRCA1, BRCA2, PALB2, P53, PTEN, CHEK2, CDH1 genes in women from 3 cities of Colombia	Alejandro Mejia
P172 Awareness and attitudes regarding breast cancer and breast self-examination among female university students: an exploration	Sabin Katpattil
P173 Musculoskeletal pain and health-related quality of life among breast cancer patients	Asmin Sha
P174 Our experience with COVID-19 infection in oncology patients	Ognjen Djurmez
P175 Tolerability of luteinising hormone releasing hormoneanalogue (LHRH) therapy in patients with early breast cancer treatedat the Institute for Oncology and Radiology of Serbia (IORS)	Marija Dimitrijevic
P176 Understanding the role of specialist follow up in early breast cancer, a retrospective review	Zhen Rong Siow